Rituximab monotherapy (375 mg/m² weekly × 4, then maintenance)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RITUXIMAB`

ID	`REG-RITUXIMAB-MONO`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MZL-2024` `SRC-NCCN-BCELL-2025`

Notes

Used in: SMZL (HCV-neg or post-DAA persistence), nodal MZL low-burden, FL low-burden when patient prefers active treatment over W&W, selected r/r low-grade NHL. HBV reactivation surveillance throughout + 12 mo post.

Used By

Indication

IND-NLPBL-1L-RITUXIMAB-MONO - IND-NLPBL-1L-RITUXIMAB-MONO
IND-PTLD-1L-REDUCE-IS - IND-PTLD-1L-REDUCE-IS
IND-SMZL-1L-RITUXIMAB - IND-SMZL-1L-RITUXIMAB

Monitoring

MON-RITUXIMAB-MONO - MON-RITUXIMAB-MONO